Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.64
(-2.31%)
AUD 0.64
(-2.31%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -7.88 Million AUD | -11.17% |
| 2023 | -7.55 Million AUD | -82.16% |
| 2022 | -4.56 Million AUD | -83.18% |
| 2021 | -2.77 Million AUD | -81.38% |
| 2020 | -1.69 Million AUD | 26.48% |
| 2019 | -1.66 Million AUD | -63.21% |
| 2018 | -1.16 Million AUD | -66.52% |
| 2017 | -693.64 Thousand AUD | 46.94% |
| 2016 | -1.32 Million AUD | -19.69% |
| 2015 | -1.38 Million AUD | -410.15% |
| 2014 | -211.79 Thousand AUD | -0.72% |
| 2013 | -210.28 Thousand AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -2.49 Million AUD | 0.0% |
| 2024 Q2 | -3.61 Million AUD | 0.0% |
| 2024 FY | - AUD | 1.47% |
| 2023 Q1 | -1.9 Million AUD | 42.59% |
| 2023 Q2 | -3.8 Million AUD | -100.0% |
| 2023 FY | - AUD | -82.16% |
| 2023 Q3 | -1.01 Million AUD | 73.28% |
| 2023 Q4 | -3.88 Million AUD | -282.78% |
| 2022 Q2 | -2.97 Million AUD | 0.0% |
| 2022 Q4 | -3.31 Million AUD | -313.68% |
| 2022 FY | - AUD | -83.18% |
| 2022 Q3 | -800.75 Thousand AUD | 73.08% |
| 2021 FY | - AUD | -81.38% |
| 2021 Q1 | -342.78 Thousand AUD | 82.14% |
| 2021 Q2 | -1.93 Million AUD | -463.54% |
| 2021 Q3 | -431.26 Thousand AUD | 77.68% |
| 2021 Q4 | -2.2 Million AUD | -410.9% |
| 2020 FY | - AUD | 26.48% |
| 2020 Q4 | -1.91 Million AUD | -460.03% |
| 2020 Q3 | -342.78 Thousand AUD | 66.74% |
| 2020 Q2 | -1.03 Million AUD | 0.0% |
| 2019 Q1 | -719.5 Thousand AUD | -5546.69% |
| 2019 Q4 | -1.43 Million AUD | -208.3% |
| 2019 Q3 | -466.23 Thousand AUD | 67.6% |
| 2019 Q2 | -1.43 Million AUD | -100.0% |
| 2019 FY | - AUD | -63.21% |
| 2018 Q2 | -1.15 Million AUD | -100.0% |
| 2018 Q1 | -575.92 Thousand AUD | -347.97% |
| 2018 Q4 | -12.74 Thousand AUD | 95.54% |
| 2018 Q3 | -285.66 Thousand AUD | 75.2% |
| 2018 FY | - AUD | -66.52% |
| 2017 Q3 | -171.55 Thousand AUD | 81.47% |
| 2017 Q2 | -925.9 Thousand AUD | -100.0% |
| 2017 Q4 | 232.25 Thousand AUD | 235.38% |
| 2017 FY | - AUD | 46.94% |
| 2017 Q1 | -462.95 Thousand AUD | -60.64% |
| 2016 Q2 | -1.03 Million AUD | -282.6% |
| 2016 FY | - AUD | -19.69% |
| 2016 Q3 | -323.3 Thousand AUD | 68.72% |
| 2016 Q1 | -270.12 Thousand AUD | -10.03% |
| 2016 Q4 | -288.18 Thousand AUD | 10.86% |
| 2015 FY | - AUD | -410.15% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | -270.12 Thousand AUD | -0.04% |
| 2015 Q4 | -245.49 Thousand AUD | 9.12% |
| 2015 Q2 | -270 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 FY | - AUD | -0.72% |
| 2013 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 176.019% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -441.465% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 78.356% |
| Biome Australia Limited | -1.57 Million AUD | -399.751% |
| Patrys Limited | -3.49 Million AUD | -125.858% |
| Orthocell Limited | -11.68 Million AUD | 32.478% |
| Imugene Limited | -147.97 Million AUD | 94.67% |
| Noxopharm Limited | -5.94 Million AUD | -32.661% |
| PYC Therapeutics Limited | -38.11 Million AUD | 79.308% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 30.199% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -9.764% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 20.732% |
| CSL Limited | 4.73 Billion AUD | 100.167% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 10.708% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -165.121% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 115.208% |
| Starpharma Holdings Limited | -12.57 Million AUD | 37.288% |
| Nanollose Limited | -1.14 Million AUD | -587.108% |
| Memphasys Limited | -3.3 Million AUD | -138.452% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -994.791% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -339.091% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -72.983% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 43.336% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -179.879% |
| Race Oncology Limited | -14.2 Million AUD | 44.469% |
| Nyrada Inc. | -4.59 Million AUD | -71.605% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 134.343% |
| Dimerix Limited | -24.95 Million AUD | 68.398% |
| PharmAust Limited | -9.45 Million AUD | 16.551% |
| Immutep Limited | -42.87 Million AUD | 81.604% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 82.334% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 59.7% |
| BTC Health Limited | 1.05 Million AUD | 847.41% |
| Acrux Limited | -7.93 Million AUD | 0.551% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 103.958% |
| Biotron Limited | -5.04 Million AUD | -56.493% |
| Tissue Repair Ltd | -5.77 Million AUD | -36.577% |
| AdAlta Limited | -5.3 Million AUD | -48.742% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 82.618% |
| Hexima Limited | -995.54 Thousand AUD | -692.263% |
| AnteoTech Limited | -11.57 Million AUD | 31.835% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 87.779% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 63.064% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -143.247% |
| Actinogen Medical Limited | -12.92 Million AUD | 38.958% |
| Immuron Limited | -6.19 Million AUD | -27.372% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -315.649% |